Latest news

• Pfizer snaps up Biohaven’s migraine drug for $1.24bn

  Pfizer will sell the migraine drug outside the US and will also gain the rights to a second drug. ... Neuroscience specialist Biohaven Pharmaceuticals has teamed up with Pfizer to commercialise its recently launched migraine drug Nurtec ODT (rimegepant)

• Biohaven gets FDA approval for migraine drug Nurtec ODT

  Biohaven Pharma has become the second drugmaker to bring an oral CGRP inhibitor to the US market for acute migraine, after the US Food and Drug Administration (FDA) approved its Nurtec ... US, which said last week the drug would be cost-effective at $4,

• Lundbeck gets US approval for migraine drug at heart of Alder takeover

  specialists aren’t rushing to switch wholesale from other migraine preventative therapies like Allergan’s Botox. ... Aimovig’s ex-US licensee Novartis didn’t break sales of the drug in its fourth quarter statement.

• Allergan gets FDA nod for first oral CGRP drug for migraine

  The US regulator has given a green light to  Ubrelvy (ubrogepant) for acute migraine with or without aura, and Ireland-domiciled Allergan says it intends to launch the drug in the ... Ubrelvy represents an important new option for the acute treatment of

• Amgen exits neuroscience R&D to focus on growth areas

  The unit scored a victory with the recent approval and launch of chronic migraine drug  Aimovig (erenumab), but earlier this year was forced to abandon its  umibecestat candidate for Alzheimer’s ... disease after trials suggested patients did worse